Advanz Pharma's Ocaliva for liver disease is no longer available in Europe after the EC revoked its conditional marketing authorisation. Despite legal challenges, the drug has been withdrawn due to concerns over its effectiveness and risks. The drug remains on the US market under accelerated approval.